openPR Logo
Press release

Monoclonal Antibody Therapeutics Market Growth by Top Key Players Pfizer, Inc., Novartis International AG, Amgen, Inc., Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc

03-20-2019 01:27 PM CET | Arts & Culture

Press release from: Coherent Market Insights

Monoclonal Antibody Therapeutics

Monoclonal Antibody Therapeutics

Increasing product launches and regulatory support for the treatment of rare diseases is expected to support growth of the monoclonal antibody therapeutics market. Several companies have received the U.S FDA approvals for drugs used in treatment of diseases ranging from cancers to rare diseases. For instance, in August 2018, Kyowa Hakko Kirin Co., Ltd received the U.S. FDA approval for Poteligeo (mogamulizumab-kpkc) for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/2403

Moreover, in August 2018, Shire plc. received the U.S. FDA approval for TAKHZYRO (lanadelumab-flyo) injection for a rare disease hereditary angioedema (HAE) in patients 12 years of age and older. Increasing focus of key players for developing monoclonal antibodies for various cancers and rare diseases is expected to boost the global monoclonal antibody therapeutics market growth over the forecast period.

Robust pipeline, success of monoclonal antibodies such as Humira (AbbVie, Inc.) and therapeutic advantages offered by these drugs over existing medications are expected to boost growth of the global monoclonal antibody therapeutics market. Moreover, key players in the market are focused on research and development of new monoclonal antibodies in order to enhance their market share. For instance, in 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.) for the treatment of a rare disease, Metastatic Merkel Cell Carcinoma (MCC). Similarly, in 2017, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of people with locally-advanced or metastatic urothelial carcinoma (mUC).

Monoclonal antibody therapeutics market is driven by active research and development of novel drugs and significant number of new drug launches and approval. There are number of monoclonal antibodies in the pipeline, which are expected to receive approval over the forecast period. For instance, manufacturers such as Amgen, Inc., Novartis International AG, Merck & Co., Inc., Eily, Lilly, and Company, and others have several monoclonal antibodies in the pipeline. Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA), expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Some of the major players operating in the global monoclonal antibody therapeutics market include, Pfizer, Inc., Novartis International AG, Amgen, Inc., Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eily, Lilly, and Company, and Bristol-Myers Squibb Company.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/2403

Detailed Segmentation:

Global Monoclonal Antibody Therapeutics Market, By Source:
Human
Humanized
Chimeric
Others
Global Monoclonal Antibody Therapeutics Market, By Therapeutic Application:
Oncology
Autoimmune Diseases
Infectious Diseases
Hematological Disorders
Others
Global Monoclonal Antibody Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Monoclonal Antibody Therapeutics Market Growth by Top Key Players Pfizer, Inc., Novartis International AG, Amgen, Inc., Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc here

News-ID: 1664795 • Views: 341

More Releases from Coherent Market Insights

Synthetic Aperture Radar (SAR) Market World's Most Trending Companies are: Airbu …
Synthetic aperture radar market refers to the space and air-based SAR that functions on the principle of transmission and reception of the reflected signals that interact with the ground and aid in the imaging, tracking, detection and characterization. SAR finds significant applications over the conventional electro optical (EO) imaging systems, primarily owing to microwaves being able to penetrate through clouds and provide consistent 24 hour, all weather data efficiency. Download PDF
Airborne Weapon Delivery Systems Market World's Top Companies: Boeing, BAE Syste …
Airborne weapon delivery systems market that have gained significant industry traction owing to investments in the procurement and development of the next generation aerial platforms that can leverage the country's defense and attack capabilities. Some of the major countries with significant defense budgets investing in these platforms include China, the U.S., Russia, France, Germany, and the UK, in turn creating a highly conducive environment for growth of the airborne weapon
Global Cryptocurrency Market By Major Companies Bitfinex, BitFury, Bitstamp, Coi …
Cryptocurrency are digital medium of exchange, alternative to conventional currencies such as US$ or Euros. These utilize digital information exchange based on the principles of cryptography, to provide secure means of transactions and in many cases provides anonymity. In 2009, Bitcoin became the first decentralized digital currency, which leads to the introduction of over thousand other digital currencies in the market. Some of the major players operating in the global cryptocurrency
Key Information On Enterprise A2P SMS Market For Organizations With Top Companie …
SMS is a discreet and universal technique of reaching everyone with the help of basic feature phone without an additional access to data services. Application-to-person (A2P) SMS is a type an SMS service that is sent from an application, mainly a web application to mobile users. A2P SMS service is primarily used for alerts, marketing messages, notifications, and flight alerts. SMS can reach any global network and is centrally invoiced,

All 5 Releases


More Releases for Monoclonal

Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024
" Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024" Report Highlights: * Significance for Monoclonal Antibodies for Cancer Treatment * Global Cancer Monoclonal Antibodies Market Overview * Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication * Global Cancer Monoclonal Antibodies Pipeline: 697 mAb * Marketed Cancer Monoclonal Antibodies: 60 * Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion The recent years have witnessed the emergence of monoclonal antibodies, which has the potential
Monoclonal Antibodies market In Depth overview by Experts 2018
The Monoclonal Antibodies market outlook of the global industry is provided based on the Monoclonal Antibodies growth drivers, constraints and threats, SWOT analysis, and Monoclonal Antibodies market share study. The drivers and constraints of Monoclonal Antibodies industry recognize the rise and fall of the Monoclonal Antibodies market. The study is served based on the Monoclonal Antibodies haggling power of buyers, haggling power of suppliers, the risk of new entrants, the
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies. In recent years the popularity
Global Monoclonal Antibodies Pipeline Insight 2015
Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality.